姜乃榕 主治醫師-論文

PUBLICATIONS
  1. Chiang NJ*, Tsai KK*, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hus C, Lin YL, Chen JS**, Shan YS, Chen LT. A Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine in Metastatic Pancreatic Adenocarcinoma -TCOG T1211 Study. European Journal of Cancer. 124:123-130, 2020. (*Co-first author)
  2. Su YY, Liu YS, Chao YJ, Chiang NJ, Yen CJ, Tsai HM. Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors. J Clin Med. 5;8(10), 2019. pii: E1633. doi: 10.3390/jcm8101633.
  3. Pao TH, Hsueh WT, Chang WL, Chiang NJ, Lin YJ, Liu YS, Lin FC. Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. BMC Cancer. 19(1):560, 2019.
  4. Chen CE, Chiang NJ, Perng CK, Ma H, Lin CH. Review of preclinical and clinical studies of using cell-based therapy for secondary lymphedema. Journal of Surgical Oncology. doi: 10.1002/jso.25661, 2019.
  5. Hung LY*, Chiang NJ*, Tsai WC, Fu CY, Wang YC, Shan YS**, Lee GB**. A microfluidic chip for detecting cholangiocarcinoma cells in human bile. Scientific Reports. 7(1): 4248, 2017. IF (2018)=4.011, 5-yr IF (2018)=4.525. (*Co-first author, **Co- corresponding author)
  6. Gopinathan P, Hung LY, Wang CH, Chiang NJ, Wang YC, Shan YS**, Lee GB**. Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform. Biomicrofluidics. 11(4):044101. IF=2.531, 5-yr IF (2018)=3.011. (**Co-corresponding author)
  7. Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT**. A Phase I Dose–Escalation Study of PEP02 (Irinotecan Liposome Injection) in Combination with 5-Fluorouracil and Leucovorin in Advanced Solid Tumors. BMC Cancer. 16(1):907, 2016. IF (2018)=2.933, 5-yr IF (2018)=3.424. (First author,
    **corresponding author)
  8. Chiang NJ*, Hsu C*, Chen JS*, Tsou HH, Shen YY, Chao Y, Chen MH, Yeh TS, Shan YS**, Huang SF**, Chen LT**. Expression level of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Scientific Reports. 3(6):25369, 2016. doi: 10.1038/srep25369. IF (2018)=4.011, 5-yr IF (2018)=4.525. (*Co-first author, **Co-corresponding author)
  9. Chiang NJ, Chang JY, Shan YS**, Chen LT**. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opinion on Pharmacotherapy. 17(10):1413-20, 2016. IF (2017)=3.475. (First author, **Co-corresponding author)
  10. Chiang NJ, Shan YS, Hung WC**, Chen LT**. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma. International Journal of Biochemistry and Cell Biolology. 67:110-114, 2015. IF (2018)=3.144, 5-yr IF (2018)=3.654. (First author, **Co-corresponding author)
  11. Chiang NJ, Wu SN**, Chen LT**. The potent activation of Ca2+-activated K+ current by NVP-AUY922 in the human pancreatic duct cell line (PNAC-1) possibly independent of heat shock protein 90 inhibition. Journal of Pharmacological Science. 127(4): 404-13, 2015. IF (2018)=2.439, 5-yr IF (2018)=2.38. (First author,
    **Co-corresponding author)
  12. Chen JS*, Hsu C*, Chiang NJ*, Tsai CS*, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Youngsen, Hsieh RK, Shan YS**, Chao Y**, Chen LT**, Taiwan Cooperative Oncology Group. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of oncology. 26(5): 943-9, 2015. IF (2018)=14.196, 5-yr IF (2018)=11.791. (*Co-first author, **Co- corresponding author)
  13. SU YY, Chiang NJ, Wu CC, Chen LT**. Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: a case report. Oncology Letters 10(4):2366-2370, 2015. IF (2018)=1.871. (**Co-corresponding author)
  14. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY**, Chen LT**. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemotherapy and Pharmacology. 78(3): 579-86, 2015. IF (2018)=3.008, 5-yr IF (2018)=2.791. (**Co-corresponding author)
  15. Chiang NJ, Wu SN**, Kao CA, Huang YM, Chen LT**. Stimulation of Electroporation- Induced Inward Currents in Glioblastoma Cell Lines by the Heat Shock Protein Inhibitor AUY922. Clinical Experimental Pharmacology and Physiology. 41(10):830-7, 2014. IF (2018)=2.336. (First author, **Co-corresponding author)
  16. Chiang NJ, Chen LT**, Tsai CR, Chang Jeffrey S**. The Epidemiology of Gastrointestinal Stromal Tumors in Taiwan, 1998-2008: A Nation-wide Registry- based Study. BMC Cancer. 14(1): 102, 2014. IF(2017)=3.288, 5-yr IF(2017)=3.679. (First author, **Co-corresponding author)
  17. Hsueh YS, Lin CL, Chiang NJ, Ko CH, Shih NY, Wang LM, Chen TS**, Chen LT**. Selecting tyrosin kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS One. 8(6):e65762, 2013. IF(2016)=2.806, 5-yr IF(2016)=3.394. (**Co-corresponding author)
  18. Chiang NJ*, Lin CI*, Liou JP, Kuo CC, Chang CY, Chen LT, Chang JY**. A Novel Synthetic Microtubule Inhibitor, MPT0B214 Exhibits Antitumor Activity in Human Tumor Cells Through Mitochondria-dependent Intrinsic Pathway. PLoS One. 8(3):e58953, 2013. 8(6):e65762, 2013. IF(2016)=2.806, 5-yr IF(2016)=3.394 (*Co- first author, **corresponding author)
  19. Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li CF, Chen LT**. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy. 9(2): 220-33, 2013. IF(2018)=11.059. (**corresponding author)
  20. Shiao HY, Chiang NJ, Hsieh HP**. Anaplastic Lymphoma Kinase (ALK) Inhibitors: New Cancer Breakthroughs for Lung Cancer. Journal of Cancer Research and Practice 27(4), 143-156, 2011. (**corresponding author)

Book Chapter

  1. Chiang NJ, Chen.LT Chapter 37: Chemotherapy in the Management of Pancreatic Cancer. Pancreatic Cancer (With Special Focus on Topical Issues and Surgical Techniques), Springer, 2017. (First author)

ABSTRACTS

  1. NJ Chiang, CP Li, YW Wang, YY Su, YS Shan, LT Chen. The Association Between UGT1A1 Polymorphisms and Treatment Toxicities from Liposomal Irinotecan (Nal- IRI; Onivyde). JSMO, Kyoto, JAPAN, 18-20 July, 2019 (Travel grand award)
  2. NJ Chiang, Priya Gopinathan, SC Hung, GB Lee, YS Shan. Using an Integrated Microfluidic Platform and a Novel Glycosaminoglycan Probe to Explore Circulating Tumor Cells (CTCs) in Cholangiocarcinoma. APCCA, Taiwan, 15-16 March, 2019
  3. NJ Chiang, CT Liu, KH Yeh, JS Chen, MH Chen, LT Chen. Molecular Profiling of Intrahepatic Cholangiocarcinoma in Taiwan Using Targeted Next-Generation Sequencing. APCCA, Taiwan, 15-16 March, 2019
  4. NJ Chiang, MH Chen, MH Tsai, HW Tsai, LT Chen YS Shan. Mutation landscape and immune profile of EBV-associated lymphoepithelioma-like cholangiocarcinoma. ASCO GI, San Francisco, USA, 17-19 January, 2019.
  5. NJ Chiang, JS Chen, MH Chen, C Hsu, SH Yang, CJ Yen, YS Shan, LT Chen. Phase II Trial of Biweekly S-1 and Gemcitabine as the First-line Treatment in Patients with Locally Advanced and Metastatic Biliary Tract Cancer (TCOG T1308 Study). ESMO Asia, Singapore, 23-25 Nov, 2018
  6. NJ Chiang, KK. Tsai, JS Chen, SH Yang, HH Hsiao, YS Shan, LT Chen. Multicenter, Phase II Trial of Biweekly S-1, Leucovorin (LV), Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (mPDAC): Final Report of TCOG T1211 Study. ESMO, Germany, 19-23 Oct, 2018
  7. NJ Chiang, HS Shiah, CC Lin, CJ Yen, HJ Tsai, SY Wu, WC Su, KY Chang, LT Chen. A Phase I Dose Escalation Study of SCB01A, a Micro-tubular Inhibitor with Vascular Disrupting Activity in Patients Advanced Solid Tumors Refractory to Standard Therapy. ASCO, Chicago, USA. 2-6 June, 2017
  8. NJ Chiang, JS Chen, MH Chen, SH Yang, C Hsu, CJ Yen, HH Tsou, YS Shan, Li-Tzong Chen. A Phase II Trial of modified Gemcitabine plus S-1 combination as the First- line Treatment in Patients with Advanced Biliary Tract Cancer. TJCC, Taiwan, 6-7 May, 2017 (Good poster award, clinical section)
  9. NJ Chiang, KK Tsai, JS Chen, SH Yang, C Hsu, YS Shan, LT Chen. Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (the SLOG regimen) in Metastatic Pancreatic Adenocarcinoma (mPDAC)-TCOG T1211 Study. TJCC, Taiwan, 14-15 May, 2016 (Good poster award, clinical section)
  10. NJ Chiang, KH Yeh, CF Chiu, JS Chen, CC Yen,KD Lee, YL Lin, LY Bai, MH Chen, TH Lin, Y Yang, KM Rau, HH Hsiao, YS Shan, LT Chen. Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) failed to imatinib and sunitinib therapy. ASCO GI 2016, San Francisco, USA, 21-23 January, 2016.
  11. NJ Chiang, KK. Tsai, JS Chen, SH Yang, C Hsu, YS Shan, LT Chen. Phase I Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (the SLOG regimen) in Metastatic Pancreatic Adenocarcinoma (mPDAC). ASCO GI 2016, San Francisco, USA, 21-23 January, 2016.
  12. NJ Chiang, JS. Chang, C Hsu, JS Chen, Y Chao, YS Shan, SF Huang, and LT Chen, On behalf of TCOG, NICR, NHRI, Taiwan. Impact of single nucleotide polymorphisms (SNPs) of drug-metabolizing genes on the therapeutic efficacy of GEMOX alone or with cetuximab in advanced biliary tract cancers. 5th Asia-Pacific Primary Liver Cancer Expert Meeting, Taipei, Taiwan, 11-13 July, 2014.
  13. NJ Chiang, C Hsu, JS Chen, HH Tsou, Y Chao, CS Tsai, YS Shan, CF Chiu, CL Ho, MS Yu, KD Lee, KM Rau, TS Yeh, IC Chang, SF Huang, LT Chen, On behalf of TCOG, NICR, NHRI, Taiwan. Impact of ROS1, ALK and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in advanced biliary tract cancers (ABTC): a post hoc analysis of a randomized phase II trial. ASCO GI 2014, San Francisco, USA, 16-18 January, 2014.
  14. CR Tsai, NJ Chiang, LT Chen, JS. Chang. The Epidemiology of Malignant Gastrointestinal Stromal Tumors in Taiwan, 1998-2008. The 72nd Annual Meeting of Japanese Cancer Association, 2013. Yokohama, Japan, 3-5 October, 2013 (Travel grant award).
  15. NJ Chiang, CI Lin, JP Liu, CC Kuo, CY Chang, LT Chen, JY Chang.. Novel Synthetic Microtubule Inhibitor, MPT0B214 Exhibited Antitumor Activity in Human Tumor Cells Through Mitochondria-dependent Intrinsic Pathway. 2012 16th Annual Meeting of the Taiwan Cooperative Oncology Group.
  16. NJ Chiang, CF Hsiao, PJ Chen, MF Chen, LT Chen. Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: post-hoc analysis from a prospective study with long-term follow-up. 2012 16th Annual Meeting of the Taiwan Cooperative Oncology Group (Accepted as Good Article Award).
Share Button

Comments are closed.